A daidzein-daunomycin conjugate improves the therapeutic response in an animal model of ovarian carcinoma

Journal of Steroid Biochemistry and Molecular Biology

Volumn 110, Issue 1-2, 2008, Pages 144-149

  Somjen, Dalia ^b   Katzburg, Sara ^b   Nevo, Nava ^a   Gayer, Batya ^a   Hodge, Richard P ^c   Renevey, Misty D ^c   Kalchenko, Vyacheslav ^a   Meshorer, Asher ^d   Stern, Naftali ^b   Kohen, Fortune ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d D Pharm Ltd   (Israel)

Author keywords

Daidzein; Daunomycin; Isoflavone; Ovarian carcinoma; Site directed chemotherapy

Indexed keywords

7 (O) CARBOXYMETHYLDAIDZEIN DAUNOMYCIN; DAIDZEIN; DAUNORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG INHIBITION; DRUG RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; FLUORESCENCE ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; NONHUMAN; OVARY CARCINOMA; TUMOR GROWTH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; DAUNORUBICIN; FEMALE; HUMANS; ISOFLAVONES; MICE; MICE, NUDE; MOLECULAR STRUCTURE; OVARIAN NEOPLASMS; PHYTOESTROGENS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS;

EID: 44649093859     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.03.033     Document Type: Article

References (20)

1. Dharap S.S., Wang Y., Chandna P., Khandare J.J., Qiu B., Gunaseelan S., Sinko P.J., Stein S., Farmanfarmaian A., and Minko T. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc. Natl. Acad. Sci. U.S.A. 102 36 (2005) 12962-12967
2. Dubowchik G.M., and Walker M.A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol. Ther. 83 2 (1999) 67-123
3. Nagy A., Schally A.V., Armatis P., Szepeshazi K., Halmos G., Kovacs M., Zarandi M., Groot K., Miyazaki M., Jungwirth A., and Horvath J. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc. Natl. Acad. Sci. U.S.A. 93 14 (1996) 7269-7273
4. Szepeshazi K., Schally A.V., Halmos G., Szoke B., Groot K., and Nagy A. Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors. Breast Cancer Res. Treat. 40 2 (1996) 129-139
5. Varga J.M., Asato N., Lande S., and Lerner A.B. Melanotropin-daunomycin conjugate shows receptor-mediated cytotoxicity in cultured murine melanoma cells. Nature 267 5606 (1977) 56-58
6. Kasiotis K.M., Magiatis P., Pratsinis H., Skaltsounis A., Abadji V., Charalambous A., Moutsatsou P., and Haroutounian S.A. Synthesis and biological evaluation of novel daunorubicin-estrogen conjugates. Steroids 66 10 (2001) 785-791
7. Kukowska-Latallo J.F., Candido K.A., Cao Z., Nigavekar S.S., Majoros I.J., Thomas T.P., Balogh L.P., Khan M.K., and Baker Jr. J.R. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 65 12 (2005) 5317-5324
8. Jaracz S., Chen J., Kuznetsova L.V., and Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg. Med. Chem. 13 17 (2005) 5043-5054
9. Allen T.M., and Cullis P.R. Drug delivery systems: entering the mainstream. Science 303 5665 (2004) 1818-1822
10. Dixon R.A. Phytoestrogens. Annu. Rev. Plant Biol. 55 (2004) 225-261
11. Somjen D., Stern N., Knoll E., Sharon O., Gayer B., Kulik T., and Kohen F. Carboxy derivatives of isoflavones as affinity carriers for cytotoxic drug targeting in adrenocortical H295R carcinoma cells. J. Endocrinol. 179 3 (2003) 395-403
12. Kohen F., Lichter S., Gayer B., DeBoever J., and Lu L.J. The measurement of the isoflavone daidzein by time resolved fluorescent immunoassay: a method for assessment of dietary soya exposure. J. Steroid Biochem. Mol. Biol. 64 3-4 (1998) 217-222
13. Chen X., and Anderson J.J. Isoflavones inhibit proliferation of ovarian cancer cells in vitro via an estrogen receptor-dependent pathway. Nutr. Cancer 41 1-2 (2001) 165-171
14. Lehtonen J.Y., Adlercreutz H., and Kinnunen P.K. Binding of daidzein to liposomes. Biochim. Biophys. Acta 1285 1 (1996) 91-100
15. Constantinou A.I., White B.E., Tonetti D., Yang Y., Liang W., Li W., and van Breemen R.B. The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours. Eur. J. Cancer 41 4 (2005) 647-654
16. Kohen F., Gayer B., Kulik T., Frydman V., Nevo N., Katzburg S., Limor R., Sharon O., Stern N., and Somjen D. Synthesis and evaluation of the antiproliferative activities of derivatives of carboxyalkyl isoflavones linked to N-t-Boc-hexylenediamine. J. Med. Chem. 50 25 (2007) 6405-6410
17. Bennetau-Pelissero C., Le Houerou C., Lamothe V., Le Menn F., Babin P., and Bennetau B. Synthesis of haptens and conjugates for ELISAs of phytoestrogens. Development of the immunological tests. J. Agric. Food Chem. 48 2 (2000) 305-311
18. Somjen D., Kohen F., Lieberherr M., Gayer B., Schejter E., Katzburg S., Limor R., Sharon O., Knoll E., Posner G.H., Kaye A.M., and Stern N. Membranal effects of phytoestrogens and carboxy derivatives of phytoestrogens on human vascular and bone cells: new insights based on studies with carboxy-biochanin A. J. Steroid Biochem. Mol. Biol. 93 2-5 (2005) 293-303
19. de Wilde A., Heberden C., Chaumaz G., Bordat C., and Lieberherr M. Signaling networks from Gbeta1 subunit to transcription factors and actin remodeling via a membrane-located ERbeta-related protein in the rapid action of daidzein in osteoblasts. J. Cell Physiol. 209 3 (2006) 786-801
20. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., van der Burg B., and Gustafsson J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139 10 (1998) 4252-4263